Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

Pariente, Benjamin; Chambrun, Guillaume Pineton de; Krzysiek, Roman; Desroches, Marine; Louis, Gauthier; Cassan, Chiara De; Baudry, Clotilde; Gornet, Jean–Marc; Desreumaux, Pierre; Émilie, Dominique; Colombel, Jean–Frédéric; Allez, Matthieu

doi:10.1002/ibd.21839

Cited by 104 publications

(83 citation statements)

References 30 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 The correlation between clinical response, IFX trough levels (IFX serum level just before next infusion) and ATI was investigated. The results of Pariente et al are also in stark contrast to previously published papers proving a correlation between IFX trough levels and clinical outcome in Crohn's disease and ulcerative colitis patients.…”

Section: Discussionmentioning

confidence: 99%

Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays

Casteele

Buurman

Sturkenboom

et al. 2012

Aliment Pharmacol Ther

187

179

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays

Casteele

Buurman

Sturkenboom

et al. 2012

Aliment Pharmacol Ther

187

179

View full text Add to dashboard Cite

show abstract

“…Th us, all patients with detectable ATI had no detectable serum IFX. In a French study utilizing a modifi ed ELISA, 6/10 patients with ATIs responded to dose escalation [50]. In a recent study evaluating the utility of IFX and ADA levels ATIs for prediction of response to intervention in LOR, only high-level antibodies (antibodies-to-adalimumab >4 mcg/mL-eq and antibodies-to-IFX >9 mcg/mL-eq) were 90% specifi c for failure to respond to dose intensifi cation [51].…”

Section: Therapeutic Drug Monitoring (Tdm) For Primary Nonresponsementioning

confidence: 99%

Therapeutic Drug Monitoring in Inflammatory Bowel Disease

2017

View full text Add to dashboard Cite

Tumor necrosis factor (TNF)-α inhibitors and thiopurines are among the most important classes of medications utilized in the clinical management of Crohn's disease and ulcerative colitis. A signifi cant proportion of patients loses response to these agents or develops adverse eff ects during the course of the treatment. Monitoring of drug levels and anti-drug antibodies (for TNF-α inhibitors) and metabolite levels (for thiopurines) can provide valuable insight into the possible etiology of unfavorable outcomes and allow for an appropriate management strategy for these patients. Th is review summarizes the current knowledge on the clinical implications of therapeutic drug monitoring in infl ammatory bowel disease patients treated with TNF-α inhibitors and thiopurines.

show abstract

“…There has been growing evidence that serum anti-TNF levels are correlated with the efficacy of IFX [16,17,55,60,[63][64][65], although there have been conflicting results [66].…”

Section: Since the Accent I (A Crohn's Disease Clinical Trial Evaluatingmentioning

confidence: 99%

Monitoring Anti-Tnf Drug Treatment in Inflammatory Bowel Disease. Is it Useful in Clinical Practice?

Martín-Arranz¹

2016

GHOA

View full text Add to dashboard Cite

Despite the efficacy demonstrated by anti-TNF drugs in treating inflammatory bowel disease, there is a significant percentage of patients for whom the drugs fail or the response to the drugs is lost. The limitations in managing these patients and the increase in costs necessitate an individualised strategy to optimise their clinical management. Recent studies have noted the relationship between the clinical outcome and therapeutic adjustments based on monitoring anti-TNF levels and the presence of antibodies, taking into account other factors such as the type of disease and its severity. This study reviews the available information and proposes a clinical management algorithm to achieve a more efficient result.

show abstract

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

Abstract: In patients with IBD who lose response to infliximab, clinical improvement may occur upon intensification of infliximab therapy, irrespective of infliximab serum concentration or presence of ATI.

Cited by 104 publications

References 30 publications

Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays

Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays

Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Monitoring Anti-Tnf Drug Treatment in Inflammatory Bowel Disease. Is it Useful in Clinical Practice?

Contact Info

Product

Resources

About